(Alameda, CA) BioTime Inc. completed a series of extensive preclinical safety and efficacy studies for its product OpRegen intended for treatment of dry age-related macular degeneration.
BioTime’s Cell Cure Neurosciences Ltd. Demonstrates Safety and Efficacy of OpRegen® in Animal Studies (Market Watch)
Age-related macular degeneration (AMD)